<i>HER2</i> Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Open Access

<i>HER2</i> Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

DOI Full Paper Access

137

Citations

29

References

2014

Year

Hee Jin Lee, An Na Seo, Eun Joo Kim, Min Hye Jang, Koung Jin Suh, Han Suk Ryu, Yu Jung Kim, Jee Hyun Kim, Seock‐Ah Im, Gyungyub Gong,

American Journal of Clinical Pathology

Abstract

These results suggest that accurate assessment of HER2 status, including HER2 heterogeneity, is important in predicting trastuzumab responses and outcomes in patients with HER2-positive metastatic breast cancer.

References

	Year	Citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. Eisenhauer, P. Therasse, Jan Bogaerts, European Journal of Cancer Surgical OncologyRecist GuidelineMedicineCancer ManagementSolid Tumours	2008	28.6K
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond, Edith A. Perez, John Bryant, New England Journal of Medicine	2005	5.3K
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Journal of Clinical Oncology	2006	4.5K
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Charles L. Vogel Journal of Clinical Oncology	2002	2.9K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer Charles L. Vogel, Melody Cobleigh, Debu Tripathy, Journal of Clinical Oncology Breast OncologySingle AgentMedicineCancer ManagementPharmacology	2002	1.8K
HER2 testing in gastric cancer: a practical approach Josef Rüschoff, Wedad Hanna, Michael Bilous, Modern Pathology Gastrointestinal OncologyMedicineCancer ManagementGastroenterologyPathology	2012	584
HER-2/neu oncogene protein and prognosis in breast cancer. Amol Tandon, Gary M. Clark, Gary C. Chamness, Journal of Clinical Oncology Gene AmplificationBreast OncologyOncogenic AgentMedicineImmunology	1989	583

Page 1